FDA Names New Director for the Office of Generic Drugs
CDER Director Janet Woodcock announced that Sally Chloe will be the new director of the Office of Generic Drugs at the end of the month.
Chloe, who served as CDER’s Office of Study Integrity and Surveillance’s deputy director for the past two years, will collaborate with outgoing OGD director Kathleen Uhl to ensure a smooth transition.
Chloe worked with the agency’s review divisions and served for five years on the Office of Clinical Pharmacology’s metabolism and endocrinology team, guiding scientists in clinical and pharmacology reviews and NDA, BLA and IND evaluations. Prior to joining the agency, she was a research manager at Bristol-Myers Squibb and a clinical pharmacology manager at Pfizer.